Ries Jutta, Vairaktaris Eleftherios, Agaimy Abbas, Kintopp Rita, Baran Christoph, Neukam Friedrich W, Nkenke Emeka
Department of Oral and Maxillofacial Surgery, Erlangen University Hospital, Erlangen, Germany.
Department of Oral and Maxillofacial Surgery, University of Athens, Athens, Greece.
Oncol Rep. 2014 Mar;31(3):1429-36. doi: 10.3892/or.2014.2983. Epub 2014 Jan 20.
microRNAs (miRNAs) are aberrantly expressed in the whole blood of patients suffering from different types of cancer. Collection of whole blood samples is a minimally invasive procedure. To date, little is known concerning the altered miRNA expression in patients suffering from oral squamous cell carcinoma (OSCC). The present study aimed to evaluate the difference in miRNA expression in whole blood samples in OSCC patients as compared to healthy volunteers who served as controls. In 20 blood samples from patients and healthy volunteers, the expression patterns of 1,205 human miRNAs were examined by miRNA microarray in order to identify those with the most pronounced differential expression. The results were verified by quantitative RT-PCR (RT-qPCR) for miR-186, miR-3651 and miR-494 using 57 samples of patients and 33 samples of healthy volunteers. Receiver operating characteristic (ROC) curves and the highest Youden index were calculated in order to assess cut-off points (COPs) that allowed the distinguishing of blood samples of OSCC patients from those of healthy volunteers. Significantly different expression rates were found for miR-186 (p=0.01), miR-3651 (p=0.0001) and miR-494 (p=0.004) between the OSCC patients and healthy controls. In the OSCC patients, there was a 2-fold upregulation for miR-494 and miR-3651 and a 2-fold downregulation for miR-186. Based on the determined COPs, significant correlations between miR-3651 overexpression and lymph node status (p=0.04), tumor grade (p=0.02) and clinical stage (p=0.04) were indicated. Aberrant expression levels of miR-186, miR-494 and miR-3651 in whole blood samples of OSCC patients may provide the possibility to establish a minimally invasive screening method for OSCC.
微小RNA（miRNA）在患有不同类型癌症的患者全血中表达异常。采集全血样本是一种微创操作。迄今为止，关于口腔鳞状细胞癌（OSCC）患者中miRNA表达的改变知之甚少。本研究旨在评估OSCC患者全血样本与作为对照的健康志愿者相比，miRNA表达的差异。在来自患者和健康志愿者的20份血样中，通过miRNA微阵列检测了1205种人类miRNA的表达模式，以鉴定那些差异表达最明显的miRNA。使用57份患者样本和33份健康志愿者样本，通过定量逆转录聚合酶链反应（RT-qPCR）对miR-186、miR-3651和miR-494的结果进行了验证。计算了受试者工作特征（ROC）曲线和最高约登指数，以评估能够区分OSCC患者血样与健康志愿者血样的截断点（COP）。在OSCC患者和健康对照之间，发现miR-186（p=0.01）、miR-3651（p=0.0001）和miR-494（p=0.004）的表达率有显著差异。在OSCC患者中，miR-494和miR-3651上调了2倍，而miR-186下调了2倍。基于确定的COP，表明miR-3651过表达与淋巴结状态（p=0.04）、肿瘤分级（p=0.02）和临床分期（p=0.04）之间存在显著相关性。OSCC患者全血样本中miR-186、miR-494和miR-3651的异常表达水平可能为建立OSCC的微创筛查方法提供可能性。
